Latest Articles
-
Retracted Publication
Increased serum vascular endothelial growth factor level in Churg-Strauss syndrome.
Churg-Strauss syndrome (CSS) is a rare form of systemic vasculitis occurring in patients with asthma and hypereosinophilia. For optimal treatment, prompt distinction of CSS from asthma is necessary; however, there are few serologic screening markers for this purpose. Vascular endothelial growth factor (VEGF), a vascular permeability factor, has been associated with other systemic vasculitis such as Wegener granulomatosis and giant-cell arteritis. ⋯ VEGF is one of the useful screening markers for the distinction of CSS from asthma. We suggest that VEGF might be associated with the pathogenesis of CSS.
-
Clin Adv Hematol Oncol · Dec 2005
Review Retracted PublicationSome ethical issues in phase II trials in acute leukemia.
This paper addresses several scientific and ethical issues that arise in the design and conduct of phase II clinical trials of experimental therapies. Although we discuss chemotherapy trials in acute leukemia, the issues pertain to a much larger class of early-phase clinical trials. ⋯ We show that statistical designs that target inappropriately low response rates or that apply early stopping rules too infrequently are at odds with good statistical and medical practice and that such designs often provide less benefit to the patients in the trial than would be obtained by simply treating all patients with standard therapy. The general conclusions are that statistical designs have both scientific and ethical implications, and that science, statistics, and ethics cannot be treated as separate issues.
-
Retracted Publication
Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease.
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article is being retracted at the request of the Editor in Chief because of the stated concerns listed below. The article was accepted for publication by a previous editor and editorial board nearly 15 years ago, at a time when submissions and documentation were in paper form, prior to the transition of The American Journal of Medicine to a digital submission and review process. ⋯ We are therefore retracting this article since the evidence presented indicates that there has been scientific misconduct. Joseph S. Alpert, MD Professor of Medicine, University of Arizona College of Medicine, Tucson, Arizona; Editor in Chief, The American Journal of Medicine
-
Retracted Publication
Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study.
Non-steroidal anti-inflammatory drugs (NSAIDs) seem to prevent several types of cancer, but could increase the risk of cardiovascular complications. We investigated whether use of NSAIDs was associated with a change in the incidence of oral cancer or overall or cardiovascular mortality. ⋯ Long-term use of NSAIDs is associated with a reduced incidence of oral cancer (including in active smokers), but also with an increased risk of death due to cardiovascular disease. These findings highlight the need for a careful risk-benefit analysis when the long-term use of NSAIDs is considered.